ALTERITY THERAP LTD ORDINARY (ATH) Short Interest
ALTERITY THERAP LTD ORDINARY (ASX:ATH) had 0.00% of shares reported as short positions as of 16 July 2026, representing 5,063 shares. ALTERITY THERAP LTD ORDINARY operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Alterity Therapeutics
Alterity Therapeutics Limited focuses on developing therapies to treat neurodegenerative diseases associated with aging, like Alzheimer's and Parkinson's disease. The company leverages a novel drug development platform aimed at targeting misfolded proteins. Positioned as a pioneer in this field, Alterity aims to address significant unmet needs in the neurosciences market.
Short position
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4ATH intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Alterity Therapeutics
Latest ATH news
All news- Biocurious: Alterity “off to the races” in quest for Multiple System Atrophy cure
stockhead
- Alterity Therapeutics (ASX:ATH) Falls as Biotech Volatility Returns to the ASX - Kalkine
googlenews
- StockTake: Alterity receives $4m R&D tax boost ahead of pivotal Phase III MSA trial
stockhead
- ATH Receives A$3.98m R&D Tax Incentive
asx
- Application for quotation of securities - ATH
asx
About
website
address
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss ATH
Start a research thread or post the first pulse update